The 2nd School of Medicine,WMU/The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
Welcome,         Profile    Billing    Logout  
 5 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lin, Ying
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

Recruiting
3
282
RoW
Catumaxomab, The treatment of investigator choice
LintonPharm Co.,Ltd.
Stomach Neoplasms
03/23
08/23
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting
3
531
RoW
JS001, Nab-Paclitaxel, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Triple-Negative Breast Cancer
12/24
12/25
NCT06520176: Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Recruiting
3
99
RoW
Etoposide, VP-16, Cytarabine, Ara-C, Pegfilgrastim, PEG-rhG-CSF, Cyclophosphamide, Cy, G-CSF, Granulocyte Colony Stimulating Factor
The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital
Multiple Myeloma, Hematopoietic Stem Cell Mobilization
12/26
12/26
NCT06520163: Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Recruiting
3
99
RoW
Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF, G-CSF, CHOP, Hyper-CVAD, ID-MTX + Ara-C, DA-EPOCH, GDP, GDPE, ICE, DICE
The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Jinhua People's Hospital, The Central Hospital of Lishui City, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital
Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization
12/26
12/26
NCT04263298: Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Recruiting
3
210
RoW
Fulvestrant, Experimental group, Capecitabine Oral Product, Active Comparator control group
Herui Yao
Metastatic Breast Cancer
05/25
05/30
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NeoTEE, NCT04465097: Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Completed
2
30
RoW
Tucidinostat, Chidamide, Epidaza, Exemestane, Ovarian function suppression
First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
10/23
10/23
IMPARP, NCT05761470: Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

Recruiting
2
66
RoW
Camrelizumab, Fluzoparib, Nab-paclitaxel
Ying Lin
Her-2 Negative Breast Cancer, HRR Gene Mutation
06/24
12/28
NCT06220630: The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study

Recruiting
N/A
1200
RoW
Breast cancer
First Affiliated Hospital, Sun Yat-Sen University, Beijing Medical Award Foundation, The Affiliated Cancer Hospital of Xinjiang Medical University, The Fourth Hospital of Hebei Medical University, The Third Affiliated Hospital of Kunming Medical University, Sun Yat-sen University, The Affiliated Cancer Hospital of Zhengzhou University, The Third Hospital of Nanchang City, Beijing 302 Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Fujian Provincial Hospital, First Hospital of China Medical University, The Affiliated Hospital of Qingdao University, Guangdong Provincial People's Hospital, First Affiliated Hospital Xi'an Jiaotong University, First People's Hospital of Foshan, Peking University First Hospital, The Affiliated Hospital Of Guizhou Medical University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Jiangmen Central Hospital, The Second Affiliated Hospital, Guangzhou Medical University, The First Affiliated Hospital, Zhejiang University, Peking University Shenzhen Hospital, The Second Affiliated Hospital of Harbin Medical University, Affiliated Sanming First Hospital of Fujian Medical University, Jieyang People's Hospital, National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Shantou Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Lianjiang Pepole's Hospital, Lianjiang, Guangdong Women and Children Hospital, Zhanjiang Central Hospital, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine
Breast Cancer
08/25
12/25
2022-YAN-030, NCT05536154: Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Recruiting
N/A
68
RoW
Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF
The Affiliated People's Hospital of Ningbo University
Lymphoma, Multiple Myeloma
06/24
10/24

Download Options